Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 DDI study with midazolam in healthy participants
NCT03916406Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-06835919 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Pfizer. Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity up to 51 days. Started Apr 2019; status: completed.
02
Drugs
PF-06835919
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03916406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916406.